A benchmark moment for medEctoin®

medEctoin® has entered the global dry eye conversation. The TFOS DEWS III Management and Therapy Report includes ectoine in a dedicated section under tear supplements and stabilisers for Dry Eye Disease management.

This recognition gives formulators a stronger scientific reference point when developing modern ocular care concepts, especially for applications focused on dry eye, tear film stability and ocular comfort.

Not a footnote. A dedicated section.

In Section 3.1.1.8, TFOS DEWS III describes ectoine as a bacteria derived extremolyte with the ability to protect proteins and biological membranes from damage caused by extreme environmental conditions. The report classifies ectoine as a natural osmoprotectant.

For medEctoin®, this is more than a mention. It places ectoine in a dedicated scientific context within one of the most relevant global references for Dry Eye Disease management.

Why this matters for formulators

Dry Eye Disease is associated with an unstable tear film, increased salt concentration in tears, inflammation and damage to the surface cells of the eye. In this environment, osmoprotectants are used to help protect proteins and cell membranes when osmotic stress becomes challenging.

With ectoine now covered in TFOS DEWS III, formulators can point to an independent scientific reference beyond supplier documentation. This supports more confident formulation development for dry eye and ocular comfort applications.

Why choose medEctoin®

medEctoin® supports formulation development for dry eye and ocular comfort concepts. It brings clinically documented ectoine expertise into modern ocular care formulation and is available for preservative free ocular care concepts in single dose and multi dose formats.

As the original manufacturer of medEctoin®, bitop provides technical expertise and formulation support for partners working in ocular care.

Ready to develop with medEctoin®?

Get in touch with our team at bd@bitop.de.